Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5009372 | 0.92 | ALDH1A1 (0.40) | KDM4EALDH1A1LMNACYP1A2CYP3A4 | |
| SCHEMBL5009367 | 0.92 | ALDH1A1 (0.40) | KDM4EALDH1A1LMNACYP1A2CYP3A4 | |
| Formic Acid SCHEMBL19466603 | 0.68 | KDM4E (0.32) | KDM4EALDH1A1LMNACYP1A2CYP3A4 | |
| SCHEMBL7343774 | 0.67 | ALDH1A1 (0.31) | ALDH1A1 | |
| SCHEMBL7344198 | 0.67 | ALDH1A1 (0.31) | ALDH1A1 | |
| SCHEMBL28468424 | 0.67 | ALDH1A1 (0.31) | ALDH1A1 | |
| SCHEMBL8596797 | 0.67 | — | — | |
| SCHEMBL8576107 | 0.67 | — | — | |
| SCHEMBL6943929 | 0.65 | — | — | |
| SCHEMBL1634085 | 0.65 | ALDH1A1 (0.41) | KDM4EALDH1A1LMNACYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10617692-B2 | Pyrrolopyrimidine comprising cyclopentyl substituent | CENTAURUS BIOPHARMA CO. (CN) | 2020-04-14 | — | — | US | disclosed |
| US-20190183899-A1 | PYRROLOPYRIMIDINE COMPRISING CYCLOPENTYL SUBSTITUENT | CENTAURUS BIOPHARMA CO., LTD. (CN) | 2019-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10617692-B2 | Pyrrolopyrimidine comprising cyclopentyl substituent | JAK1, JAK2, JAK3 | KDM4E 450/4885ALDH1A1 814/4885LMNA 4872/4885 |
| US-20190183899-A1 | PYRROLOPYRIMIDINE COMPRISING CYCLOPENTYL SUBSTITUENT | JAK1, JAK2, JAK3 | KDM4E 450/4885ALDH1A1 814/4885LMNA 4872/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.